{"id":20969,"date":"2023-08-07T04:29:00","date_gmt":"2023-08-07T04:29:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4176277_CN76277_0"},"modified":"2023-08-07T04:29:00","modified_gmt":"2023-08-07T04:29:00","slug":"the-eclinical-medicine-of-lancet-published-phase-2-results-of-ivonescimab-for-the-treatment-of-nsclc","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=20969","title":{"rendered":"The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC"},"content":{"rendered":"
\n

HONG KONG<\/span><\/span>, Aug. 7, 2023<\/span><\/span> \/PRNewswire\/ — Akeso Inc. (“Akeso”, the “Company”; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that eClinical Medicine<\/i><\/b>(IF:15.1)<\/i>, a sub-journal of The Lancet<\/i><\/b>, recently published the results of a phase II clinical trial of ivonescimab(PD-1\/VEGF bispecific antibody) combined with chemotherapy for the treatment of non-small cell lung cancer (NSCLC). The study was led by Professor Li Zhang<\/span> of the Sun Yat-Sen University Cancer Center.<\/p>\n

Full article: https:\/\/authors.elsevier.com\/sd\/article\/S2589537023002833<\/a><\/p>\n

Ivonescimab is the world’s first PD-1\/VEGF bispecific antibody for which a New Drug Application (NDA) has been submitted. Based on the published results, the combination of ivonescimab and platinum-doublet showed promising antitumor activity for first-line treatment of advanced NSCLC without driver mutation, as well as for advanced NSCLC patients with EGFR-activating<\/span> mutation that failed prior EGFR-TKI therapy. Additionally, AK112 in combination with docetaxel has shown favorable antitumor activity in advanced NSCLC patients who failed prior treatments with systemic platinum-based chemotherapy and PD-1\/L1 inhibitor.<\/p>\n

Following the acceptance of marketing application for an indication of ivonescimab by the China CDE, five pivotal registrational Phase III clinical trials have been initiated\/are being conducted worldwide, including three head-to-head trials with PD-1 monoclonal antibody as the positive control drug and two international multicenter Phase III clinical trials:<\/p>\n